Skystar Bio-Pharmaceutical Co SKBI

Similar documents
Skystar Bio-Pharmaceutical Co SKBI

Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF

Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF

DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM

(3) Educational Activities or Lectures for this Company Generates Revenue for Duke $5K $25K >$25K

DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM

THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EASTERN-EUROPE EDITION)

GLOBAL MARKETS AND TECHNOLOGIES FOR ADVANCED DRUG DELIVERY SYSTEMS

Method of Declaration. Hospitality/Interest/Sponsorship

Please complete the applicable rows in the following table. Monetary amounts are on an annual basis.

Please complete the applicable rows in the following table. Monetary amounts are on an annual basis.

DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM

DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM

Gilead Sciences. Very interesting in all areas. COMPANY Gilead Sciences Inc. INDUSTRY Biotechnology TYPE Public Company TICKER NasdaqGS:GILD

Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

State of Licensing 2011 Update

Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile

DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM

The 2011 EU industrial R&D investment SCOREBOARD

KKR & Co. Inc. Goldman Sachs U.S. Financial Services Conference December 4, 2018

PwC Deals $42B. Global Pharma & Life Sciences Deals Insights Q Update

Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Early Valuation. Company Portfolio

4 th Quarter Earnings Conference Call

Mixed Signals: Understanding the Outlook for Pharma R&D Spending Through

Management to Host Conference Call at 8:30 a.m. ET today

Annual Press Conference Financial year 2017

Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D

Investor Presentation. November 2018

Reference List Cha, Myoung., and Theresa Lorriman. February Why Pharma megamergers work. McKinsey&Company Our insights. Ward, Andrew.

Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Associate Director. Biomarker Operations Lead. Business Development & Strategic Alliances. Business Development Executive

KKR & Co. L.P. Morgan Stanley Financials Conference: June 13, 2018

2 nd Quarter Earnings Conference Call

Faes Farma SA (FAE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

HBM Healthcare Investments Ltd Access to a Global and Diversified Private Equity Healthcare Portfolio

Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

UBS Pathfinders Trust, Treasury and Growth Stock Series 23

Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Mesa Laboratories, Inc. (MLAB) - Medical Equipment - Deals and Alliances Profile

The 2010 EU industrial R&D investment SCOREBOARD

Textron Reports Third Quarter 2014 Income from Continuing Operations of $0.57 per Share, up 62.9%; Revenues up 18.1%

Phoenix Semiconductor Philippines Corp (PSPC) to be listed on December 1, Semiconductor historical billings report in 000 US$

NOT FOR DISTRIBUTION IN THE USA,CANADA, JAPAN OR AUSTRALIA

Born Ph.D. from Karolinska Institutet in Stockholm. Board member since 2016.

Textron Reports Second Quarter 2014 Income from Continuing Operations of $0.51 per Share, up 27.5%; Revenues up 23.5%

Mesa Laboratories, Inc. (MLAB) - Medical Equipment - Deals and Alliances Profile

Investor Presentation & Financial Highlights. November 2018

4 th Quarter Earnings Conference Call

Booz & Company 30 October, Making Ideas Work. The 2012 Global Innovation 1000 Study

North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Bessemer Venture Partners - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Confirms 2013 Financial Guidance

Discovery: From Concept to the Patient - The Business of Medical Discovery. Todd Sherer, Ph.D.

Life Sciences CONFERENCE SERIES. Business Information in a Global Context LIFE SCIENCES IP PORTFOLIO. Business Development Pack

PROTECT Project. Joanna Groves Chief Executive Officer 27 April 2010 EFPIA Patient Think-Tank Brussels, Belgium

KOHLBERG CAPITAL CORPORATION. May 2007

Life Sciences. An evolving industry: Today s clusters creating tomorrow s breakthroughs. New Jersey JLL Research

TRENDS IN IP DISPUTES

European companies outpace American counterparts in R&D investment growth for the first time in five years

Interim Report. 1 January 31 March Sales reached 3,006 MSEK (3,317) Sales were flat in local currencies. Continued volume growth for snuff

Textron Reports First Quarter 2016 Income from Continuing Operations of $0.55 per Share, up 19.6%; Reaffirms 2016 Financial Outlook

Investor Presentation. April 2015

Life Sciences Outlook

Accelerating Pharmaceutical Growth through Open Innovation and Global Collaborations

Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

WORLD BANK GROUP SENIOR MANAGEMENT TEAM AND VICE PRESIDENTS. FINANCIAL DISCLOSURE FOR CALENDAR YEAR 2011 Summary for Public Disclosure

Greater Yuma EDC Investors Making News

1 st Quarter Earnings Conference Call

Voting Procedure (con t)

Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Scripps Networks Interactive Inc.

Aqua Pharmaceuticals, LLC

GameStop Corp. NASDAQ:GME. HOLD Price Target: $28.74 Key Statistics as of 10/13/2016. Catalysts: Company Description:

Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting

Biotech Concerto #6 Investment Process December 2008

Industrial Investment in Research and Development: Trends and Prospects

Activision Blizzard, Inc. ATVI NASDAQ Neutral-2

KKR & Co. L.P. Morgan Stanley Financials Conference June 2014

Q4 & FY18 PERFORMANCE HIGHLIGHTS JUNE 2018

For personal use only. EBOS Group Limited. 94 th Annual Meeting. 19 October 2016

Capcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) Financial Highlights for the Fiscal Year ended March 31, 2018

Speakers Bio: Jenny Tian Managing Director

MASTERCARD INC FORM 8-K. (Current report filing) Filed 09/11/08 for the Period Ending 09/09/08

Pharmaceutical Co., Ltd. MEDICINE CNS/ENDOCRINOLOGY DEVELOPMENT LICENSING COMPANY PROFILE

NVESTOR. 1,400+ Attendees. 2,700+ Partnering Meetings. 768 Companies. 700 Registered Investors. 158 Company Presentations

Overview of Venture Equity

ANNUAL GENERAL MEETING 27 JULY Copyright Tate & Lyle PLC 2017

Pharmaxis Ltd (PXS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Corporate Profile January 2011 OTCBB:LBMH

4 th Quarter Earnings Conference Call

Holiday Trading Hours

2009 Half Year Results Summary

MOVING WATER. MOVING FUEL. MOVING FORWARD.

BRUKER CORP FORM 8-K. (Current report filing) Filed 06/07/12 for the Period Ending 06/04/12

Generics Series: Authorized Generics Analysis Stemming the Generics Tide

CASI Pharmaceuticals, Inc.

SAA s Structured Peer Group Analysis. STRATEGIC ASSET ALLIANCE, INC. Document not to be reproduced without the explicit consent of SAA.

4 th Quarter Earnings Conference Call

Transcription:

Morningstar Analyst Rating Page 1 of 6 Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 0.01 [0.00 0.00 % $ 0.01 0.01-0.01 0.00-0.20 86969.42 15,594 8,393 0.03 0.1 Stock Price 2017-01-02-2017-11-24 PINX:SKBI: -0.09-90.00% 2017 Morningstar s Take Key Stats Stock Ind Avg Price/Earnings TTM 0.2 24.5 Price/Book 4.3 Price/Sales TTM 4.1 Rev Growth (3 Yr Avg) -3.7-1.6 Net Income Growth (3 Yr Avg) -9.3-9.6 Operating Margin % TTM 25.7 21.2 Net Margin % TTM 22.5 16.9 ROA TTM 7.2 6.9 ROE TTM 9.6 17.9 Debt/Equity 0.6 Financials 3.00 2.00 1.00 Fair Value Estimate $ - Consider Buying $ - Consider Selling $ - Fair Value Uncertainty Economic Moat Stewardship Growth C Profitability V Morningstar Credit Rating Relative to Industry - Avg + Annual Quarterly Income Statement 2013-12 2012-12 2011-12 2014-09 2013-09 Revenue 42 34 53 18 16 Operating Income 13 9 15 5 5 Net Income 11 6 14 5 4 Earnings Per Share 1.37 0.83 1.90 0.57 0.49 Shares Outstanding 8 7 7 9 8 Dividends Declared Date -- Ex-Dividend Date -- Latest Indicated Dividend Amount Projected Yield % Recent Dividends & Type Amount Splits 11/17/2009 Split 2:1 05/18/2009 Split 1:10 02/16/2006 Split 1:397 11/26/2001 Split 1:15 Competitors Name Price % Chg TTM Sales $ mil Skystar Bio- $0.01 0.00 49 Pharmaceutical Co Johnson & Johnson $138.01 0.52 ] 74,361 Roche Holding AG ADR $31.60-0.19 [ 53,017 Roche Holding AG Dividend Right Cert. $252.70 0.02 ] 53,017 Roche Holding AG $252.84 0.85 ] 53,017 Pfizer Inc $35.49 0.17 ] 52,471 Recommendations Current Total Analysts: 5.0 3.0 1.0 Buy Hold Sell Ownership Fund Owners Insiders Star Rating % Change TTM % Shares Held % Total Assets % Shares Outstanding Weibing Lu 249,974 16.36 R. Scott Cramer 0 1.43 Wei Wen 0 0.96 Mark D. Chen 23,890 0.31 Bing Mei 7,999 0.30 Balance Sheet Current Assets 89 72 59 121 89 Non Current Assets 48 44 45 51 48 Total Assets 136 116 104 172 136 Current Liabilities 25 17 15 48 28 Total Liabilities 26 20 16 49 29 Stockholders' Equity 110 96 88 123 107 Cash Flow Cash From Operations -5 6-2 5 1 Capital Expenditures -0-1 -8-1 -0

Morningstar Analyst Rating Page 2 of 6 Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 0.01 [0.00 0.00 % $ 0.01 0.01-0.01 0.00-0.20 86969.42 15,594 8,393 0.03 0.1 Financials Annual Quarterly Free Cash Flow -6 5-9 4 1 In millions except "EPS". Currency in USD.

Page 3 of 6 Industry Classification NAICS Pharmaceutical Preparation Manufacturing (325412) SIC Pharmaceutical and Medicine Industry (3741);Pharmaceutical Preparations (2834) ISIC Manufacture of Pharmaceuticals, Medicinal Chemical and Botanical Products (2100) Operation Details Fiscal Year Ends 2014-12-31 CIK 1076939 Year Established Employees (31/12/2013) Full Time Part Time Auditor (31/12/2013) Crowe Horwath (HK) CPA Limited Legal Advisor (06/05/2008) Richardson & Patel LLP Key Executives Weibing Lu/Chairman of the Board and Chief Executive Officer; Wei Wen/Secretary; Bing Mei/Chief Financial Officer Company Profile Skystar Bio-Pharmaceutical Company is a holding company engaged in research, development, manufacturing and distribution of veterinary health care and medical care products in the People's Republic of China. 30-day Avg Volume 0.0Mil Market Cap Net Income 11.0Mil Sales 49.1Mil Sector Healthcare Industry Drug Manufacturers - Major Stock Style 0 Direct Investment No Dividend Reinvestment No

Page 4 of 6 Industry Peers Morningstar Rating Market Cap $Mil Net Income $Mil P/S P/B P/E Dividend Yield% 5 Yr Rev CAGR% Med Oper. Margin% Interest Coverage Skystar Bio-Pharmaceutical Co 11 0.0 0.2 10.7 30.6 22.1 Johnson & Johnson (USD) QQ 370,766 15,827 5.1 5.0 24.0 2.4 2.0 26.1 28.3 0.4 Roche Holding AG (USD,CHF) QQQQQ 214,452 9,675 4.1 9.3 22.0 3.2 3.5 28.7 19.9 0.7 Roche Holding AG (USD,CHF) 214,452 9,675 4.1 9.3 22.0 3.2 3.5 28.7 19.9 0.7 Roche Holding AG (USD,CHF) 214,452 9,675 4.1 9.3 22.0 3.2 3.5 28.7 19.9 0.7 Pfizer Inc (USD) QQQ 211,545 9,809 4.1 3.5 21.9 3.6-2.8 27.2 8.0 0.6 Novartis AG (USD) QQQ 198,993 6,543 4.1 2.9 31.1 3.2-3.6 20.7 12.1 0.3 Novartis AG (USD) 198,993 6,543 4.1 2.8 30.8 3.2-3.6 20.7 12.1 0.3 AbbVie Inc (USD) QQQ 151,213 6,648 5.6 22.6 23.0 2.7 8.0 31.6 8.5 5.1 Merck & Co Inc (USD) QQQQ 148,073 2,845 3.8 3.9 52.3 3.5-3.7 15.8 7.7 0.6 Sanofi SA (USD,EUR) 115,449 9,202 2.7 1.7 20.5 3.7-0.2 17.9 21.7 0.3 Sanofi SA (USD,EUR) QQQQ 115,449 9,202 2.7 1.7 21.0 3.6-0.2 17.9 21.7 0.3 Bayer AG (USD,EUR) 105,570 7,641 2.0 2.4 22.8 2.3 5.1 10.7 9.6 0.3 Bayer AG (USD,EUR) QQQQ 105,570 7,641 2.0 2.4 22.9 2.3 5.1 10.7 9.6 0.3 Bristol-Myers Squibb Company (USD) QQQ 100,542 4,229 5.0 6.8 24.1 2.5-1.8 16.3 36.4 0.5 Eli Lilly and Co (USD) QQQ 92,524 2,224 4.0 6.2 40.0 2.5-2.7 18.1 19.2 0.7 GlaxoSmithKline PLC (USD,GBP) QQQQ 84,410 2,335 2.2 50.1 27.8 5.9 0.4 26.5 3.8 11.0 GlaxoSmithKline PLC (USD,GBP) 84,410 2,335 2.2 50.3 28.0 5.8 0.4 26.5 3.8 11.0 AstraZeneca PLC (USD) 83,934 3,542 1.8 2.7 35.4 1.9-7.3 16.6 6.2 1.2 AstraZeneca PLC (USD) 83,927 3,542 3.8 6.1 23.7 4.2-7.3 16.6 6.2 1.2 AstraZeneca PLC (USD) QQ 83,927 3,542 3.8 6.2 24.3 4.1-7.3 16.6 6.2 1.2 Chugai Pharmaceutical Co Ltd (USD,JPY) 27,320 67,704 4.9 3.8 37.4 1.2 5.7 17.4 866.7 0.0 Chugai Pharmaceutical Co Ltd (USD,JPY) 27,320 67,704 5.9 4.5 45.2 1.0 5.7 17.4 866.7 0.0 Astellas Pharma Inc (USD,JPY) 25,711 185,754 2.2 2.1 15.7 6.2 16.5 143.6 Astellas Pharma Inc (USD,JPY) 25,450 185,754 2.3 2.1 15.9 1.2 6.2 16.5 143.6 Otsuka Holdings Co Ltd (USD,JPY) 23,904 57,992 2.2 1.5 45.7 2.0 9.4 9.9 0.1 Otsuka Holdings Co Ltd (USD,JPY) 23,904 57,992 2.2 1.5 46.1 1.0 9.4 9.9 0.1 Daiichi Sankyo Co Ltd (USD,JPY) 15,804 38,758 1.8 1.5 45.0 0.3 10.9 12.4 0.2 Daiichi Sankyo Co Ltd (USD,JPY) 15,540 38,758 1.8 1.4 44.1 1.3 0.3 10.9 12.4 0.2 CSPC Pharmaceutical Group Ltd (USD,HKD) 12,676 2,380 7.4 9.2 41.5 38.7 18.4 64.2 0.0 Ono Pharmaceutical Co Ltd (USD,JPY) 10,533 53,884 5.0 2.2 23.1 0.8 10.9 18.7 287.7 0.0 Ono Pharmaceutical Co Ltd (USD,JPY) 10,533 53,884 5.3 2.3 24.5 10.9 18.7 287.7 0.0 Kyowa Hakko Kirin Co Ltd (USD,JPY) 10,129 21,949 3.1 1.7 48.7 1.3-0.0 12.0 722.1 Recordati (USD,EUR) 9,018 274 6.0 6.9 27.5 1.8 8.7 23.4 40.2 0.5 Santen Pharmaceutical Co Ltd (USD,JPY) 6,244 25,813 3.3 2.6 27.4 0.8 11.7 21.1 21.3 Santen Pharmaceutical Co Ltd (USD,JPY) 6,244 25,813 3.3 2.6 26.8 11.7 21.1 21.3 PT Kalbe Farma Tbk (USD,IDR) 5,748 2,376,473 3.7 5.9 31.5 1.4 12.2 16.0 172.4 0.0 PT Kalbe Farma Tbk (USD,IDR) 5,748 2,376,473 3.5 5.5 29.3 12.2 16.0 172.4 0.0 Hutchison China Meditech Ltd (USD) 4,172 12 15.2 19.0 269.3 5.5-5.5-28.0 0.1 Hutchison China Meditech Ltd (USD) 4,172 12 17.7 22.2 314.5 5.5-5.5-28.0 0.1 GW Pharmaceuticals PLC (USD,GBP) 2,887-107 311.4 7.7-19.0-133.0-497.1 0.0 GW Pharmaceuticals PLC (USD,GBP) 2,887-107 277.0 6.9-19.0-133.0-497.1 0.0 Dechra Pharmaceuticals PLC (USD,GBP) 2,526 26 4.4 5.2 60.3 0.7 23.6 11.0 20.6 0.6 Aerie Pharmaceuticals Inc (USD) 2,249-115 14.1-38.0 0.8 Cosmo Pharmaceuticals NV (USD,EUR) 2,118-3 31.3 4.0 15.1 31.0 230.1 0.0 Haw Par Corp Ltd (USD,SGD) 1,813 129 11.8 0.9 20.2 1.6 8.7 68.4 356.1 Haw Par Corp Ltd (USD,SGD) 1,813 129 11.5 0.9 19.6 8.7 68.4 356.1 Tong Ren Tang Technologies Co Ltd (USD,CNY) 1,784 581 2.5 2.6 20.8 1.6 19.2 21.3 93.2 0.2 Boiron SA (USD,EUR) 1,661 76 2.3 3.0 18.4 3.3 21.1 0.0 United Laboratories International Holdings Ltd (USD,CNY) 1,450-156 1.1 1.2 4.1 7.6 0.4 0.6 D/E

Page 5 of 6 Industry Peers Zogenix Inc (USD) 1,328-110 46.6 22.3-5.1-136.1-23.6 0.2 TherapeuticsMD Inc (USD) 1,296-78 70.5 8.7 56.1-422.9 Virbac SA (USD,EUR) 1,094 35 1.2 2.2 29.1 6.9 14.1 3.6 1.0 Retrophin Inc (USD) 843-50 5.7 2.8-0.9 0.1 Nichi-Iko Pharmaceutical Co Ltd (USD,JPY) 824 5,059 0.6 1.2 24.7 1.8 7.4 24.6 0.9 Vectura Group PLC (USD,GBP) 821-10 3.7 0.9 10.9-14.5-2.8 Torii Pharmaceutical Co Ltd (USD,JPY) 758 3,855 1.3 1.0 21.7 1.6 7.9 Vetoquinol SA (USD,EUR) 724 28 1.7 1.9 21.6 0.8 4.3 10.9 89.8 0.0 Mayne Pharma Group Ltd (USD,AUD) 719 88 1.6 0.7 10.3 62.2 16.4 11.1 0.3 Tempo Scan Pacific Tbk (USD,IDR) 611 518,924 0.9 1.7 15.7 2.7 9.6 9.0 0.0 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co 541 142 5.9 4.5 26.9 1.1 36.0 26.4 38.1 Ltd (USD,CNY) Eco Animal Health Group PLC (USD,GBP) 520 10 6.2 4.1 36.2 0.8 16.7 14.7 AB Science (USD,EUR) 440-26 191.5 14.1 6.4-792.0-57.5 Rockwell Medical Inc (USD) 328-21 5.8 8.0 1.7-37.9 Allergy Therapeutics PLC (USD,GBP) 239-2 9.2-0.6-26.7 0.1 Daiken Medical Co Ltd (USD,JPY) 204 1,130 3.0 3.6 21.0 5.2 20.3 431.6 0.2 Opthea Ltd (USD,AUD) 108-6 2.7 SymBio Pharmaceuticals Ltd (USD,JPY) 103-3,943 4.8 2.2 4.7-89.8-577,357.2 Alimera Sciences Inc (USD) 87-20 2.2-282.5-5.4 PhotoCure ASA (USD,NOK) 68-3 3.6 2.3 4.7-16.3 Oasmia Pharmaceutical AB (USD,SEK) 62-155 3,180.9 1.2-28.0-43,453.3-10.9 Nanoviricides Inc (USD) 62-9 3.4-12.2 Pharmaxis Ltd (USD,AUD) 62-18 6.3 23.8 55.4-166.8-28.4 2.3 Moberg Pharma AB (USD,SEK) 60 0 1.5 1.3 43.0 11.2 3.4 1.1 Futura Medical PLC (USD,GBP) 42-3 68.1 2.8 1.5-3,274.6 Tonix Pharmaceuticals Holding Corp (USD) 34-23 1.2 ProPhase Labs Inc (USD) 28 40 1.7 0.8 2.6 3.8-12.6-12.5 NeuroVive Pharmaceutical AB (USD,SEK) 23-86 4,116.2 1.4-69.8-2,144.2-944.3 Avivagen Inc (USD,CAD) 22-4 92.4-11.0-1,420.3-18.2 Sunwin Stevia International Inc (USD) 19-4 1.1 1.7 8.4-27.1-8.9 0.2 Immune Pharmaceuticals Inc (USD) 15-26 26.8-432,759.2-23.1 3.0 Innovus Pharmaceuticals Inc (USD) 15-8 1.6 12.5-474.2-1.1 Alliqua BioMedical Inc (USD) 10-31 0.4 0.4 58.3-398.5-12.0 China Pharma Holding Inc (USD) 8-8 0.6 0.1-28.1-56.7-9.4 0.1 Biostar Pharmaceuticals Inc (USD) 4 0 14.9 0.1 2.7-51.8-44.2-13.8 Antisense Therapeutics Ltd (USD,AUD) 4-2 6.6 2.1-154.3 Aoxing Pharmaceutical Co Inc (USD) 3-1 0.1 0.2 37.2-3.5 0.0 Integrated Biopharma Inc (USD) 3 1 0.1 2.6 5.1 4.5 3.4 Enzyme Bio Systems (USD) 2 0 12.1-5,320.8 Echo Therapeutics Inc (USD) 0-6 -46,336.0-1,445.6 Nutrastar International Inc (USD) 0 23 0.0 0.0 23.1 65.1 AtheroNova Inc (USD) -10-12.0 Nouveau Life Pharmaceuticals Inc (USD) 0 0.1 Winston Pharmaceuticals Inc (USD) -2-676.6 Hubei Minkang Pharmaceutical Ltd (USD) 0 5.1 4.9 5.0 1.3 China Health Resource Inc (USD) 0 99.5 12.5 9.4 Kun Run Biotechnology Inc (USD) 4 41.0 13.8 Enzymes American Holding Corp Cell Tech International Inc (USD) -4-21.4-13.4-13.2 Biotie Therapies Corp (USD,EUR) -44 97.4 4.0 13.8-522.0-41.1 0.3 Laxai Pharma Ltd (USD) -1 1.0 Tongli Pharmaceuticals (USA) Inc (USD) 0 21.7 59.9 CSPC Pharmaceutical Group Ltd (USD,HKD) 2,380 5.4 6.7 31.9 1.1 38.7 18.4 64.2 0.0

Page 6 of 6 Industry Peers Canopus Biopharma Inc JinZangHuang Tibet Pharmaceuticals Inc (USD) 7 29.9 GFR Pharmaceuticals Inc (USD) 1 5.9 44.6 Global Pharmatech Inc (USD) -3-59.9 Somatic Systems Inc Emerging World Pharma Inc InterNatural Pharmaceuticals Inc Neurogenesis Inc Pharmaconnect Inc Innovative Holdings Alliance Inc Endocan Corp (USD) -5-0.7 Genex Pharmaceutical Inc (USD) 0 35.8 Opthea Ltd (USD,AUD) -6 27.0 Cipla Ltd (USD,INR) 11,444 15.8 14.3 14.9 0.3 Bohai Pharmaceuticals Group Inc (USD) 23 0.1 0.4 28.8 19.6 14.8 0.0 Star Nutrition Inc Shandong Luoxin Pharmaceutical Group Stock Co Ltd (USD,CNY) 344 1.5 2.2 13.8 3.9 20.4 19.0 5,394.3 Adia Nutrition Inc Merck Tbk (USD,IDR) 157,480 2.4 20.6 Shandong Luoxin Pharmaceutical Group Stock Co Ltd (USD,CNY) 344 1.9 3.0 24.6 20.4 19.0 5,394.3 Beximco Pharmaceuticals Ltd (USD,BDT) 1,803 18.1 23.8 4.3 0.1 Torrent Pharmaceuticals Ltd (USD,INR) 8,265 17.7 20.2 6.4 0.5 Piramal Enterprises Ltd (USD,INR) 14,016 31.5 16.2 1.7 1.5 GlaxoSmithKline Pharmaceuticals Ltd (USD,INR) 3,368 18.7 1,542.6 0.0 Il Yang Pharmaceutical Co Ltd (USD,KRW) 4,123 8.6 4.0 0.0 Pierrel SpA (USD,EUR) -8-21.0-21.2 Whanin Pharm Co Ltd (USD,KRW) 22,586 5.1 17.5 Shandong Xinhua Pharmaceutical Co Ltd (USD,CNY) 206 6.4 1.5 3.5 0.4 Mayne Pharma Group Ltd (USD,AUD) 88 62.2 16.4 11.1 0.3 Kyowa Hakko Kirin Co Ltd (USD,JPY) 21,949-0.0 12.0 722.1 Xi An 38 Fule Health & Advisory Co Ltd Alfresa Holdings Corp (USD,JPY) 31,359 1.8 1.4 430.7 0.0 Dong Xin Bio-Tech Pharmaceutical Inc Dawnrays Pharmaceutical (Holdings) Ltd (USD,CNY) 283-5.3 40.6 2,123.9 Artec Inc NV Global Green Inc (USD) 0-6.3 Industry Average 36,468 52,184 4.1 4.3 24.5 3.2 8.5-4,590.0-5,592.7 0.6